NICE Macular Oedema (Branch Retinal Vein Occlusion) Final Technology Appraisal
Response to NICE announcing their positive final guidance for Eylea® for the treatment of adult patients with visual impairment due to macular oedema secondary to branch retinal vein occlusion (BRVO) The Royal College of Ophthalmologists welcomes the Final Appraisal Determination (FAD) from NICE recommending Eylea (aflibercept) as a first-line treatment option for patients with visual
NCAS is recruiting for lead assessors
The National Clinical Assessment Service is seeking to recruit up to 50 Lead Assessors to be part of the NCAS Lead Assessor panel. Lead Assessors will work with their broad specialty area as part of a small assessment team to conduct clinical assessments of doctors, dentists and pharmacists where there are concerns about an individual’s
NICE accredited guidance on commissioning glaucoma services
The Royal College of Ophthalmologists and Clinical Council for Eye Health Commissioning publish NICE accredited guidance on commissioning glaucoma services Clinical Commissioners are asked to review existing services against the recommendations contained in the new guidance to ensure the most cost effective and resource efficient services are available to meet demand. The NEW Commissioning
Quality standard for people with sight loss and dementia in an ophthalmology department
This Quality standard for people with sight loss and dementia in an ophthalmology department has been developed by The Royal College of Ophthalmologists and VISION 2020 UK to help ophthalmology departments provide high quality care for patients with dementia. Patients with dementia can benefit from being identified in advance of attending their appointment in order
Response to NICE guidance on Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears
Ciclosporin (1mg/ml, Ikervis®) is a sterile, positively charged, oil-in water, unpreserved ophthalmic emulsion for the treatment of severe keratitis in adult patients with dry eye disease, which has not improved despite treatment with tear substitutes. It is administered as a once daily eye drop at bed time. The Royal College of Ophthalmologists welcomes the decision